Background: The objective of this study is to determine the role of tumor marker density (TMD) values such as alpha-fetoprotein tumor volume ratio (ATVR), beta-human chorionic gonadotropin tumor volume ratio (βTVR), alpha-fetoprotein testicle size ratio (ATSR), beta-human chorionic gonadotropin testicle size ratio (βTSR), lactate dehydrogenase tumor volume ratio (LTVR), and lactate dehydrogenase testicle size ratio (LTSR) in the determination of progression-free survival (PFS) in patients with testicular cancer.
Materials and methods: A retrospective study was conducted of 95 patients followed-up in our clinic with a diagnosis of testicular cancer between January 2015 and August 2022. Patients were grouped according to clinical stage, as either early stage (n = 50) or advanced stage (n = 45). Clinical and pathological data and TMD values for all patients were recorded.
Results: The median age of patients was 35 years (21-63 years). All TMDs except LTVR in advanced stage patients were found to be significantly higher than those of early stage patients (p < 0.05). Median ATVR (2.58 vs. 0.0), ATSR (0.63 vs. 0.03), βTVR (0.9 vs. 0.009), and βTSR (0.18 vs. 0.007) of the nonseminoma patients were found to be significantly higher than those of the seminoma patients, respectively (p < 0.001). Progression-free survival (months) was decreased in seminoma patients with high values of βTVR (11.3 ± 1.9 vs. 35.2 ± 0.7), βTSR (16.2 ± 3.4 vs. 35.2 ± 0.75), LTVR (17.7 ± 3.4 vs. 35.2 ± 0.7), and LTSR (21.5 ± 3.13 vs. 35.09 ± 0.8) (p < 0.001). Decreased PFS (months) was associated with higher values of ATVR (5.37 ± 0.7 vs. 35.05 ± 0.93), βTVR (7.4 ± 1.5 vs. 34.6 ± 1.3), ATSR (5.37 ± 0.75 vs. 35.05 ± 0.9), βTSR (7 ± 1.5 vs. 34.6 ± 1.3), and LTSR (7.9 ± 1.2 vs. 34.3 ± 1.5) in nonseminoma patients (p < 0.001). Based on multivariate analysis, βTVR-LTVR and ATVR-ATSR were determined to be independent risk factors for reduced PFS in seminoma and nonseminoma patients, respectively (p < 0.05).
Conclusions: The results of this study suggest that the calculation of TMDs could be a promising and simple method for prediction of PFS among testicular cancer patients.
Acknowledgments
None.
Statement of ethics
Approval for the study was granted by the Ethics Committee of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Decision no: 2022-08/2003). All study procedures were performed in compliance with the Helsinki Declaration. All study participants provided informed consent.
Conflict of interest statement
No conflict of interest has been declared by the authors.
Funding source
There was no external funding received in the conduct of this study.
Author contributions
AD: concept, study design, data collection, analysis, writing;
AD, HB: supervision, critical review.
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.
| [1] |
Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014; 65(6):1095-1106.
|
| [2] |
Cancer Research UK. Testicular cancer statistics [internet]. Cancer Research UK [updated February 2018]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/testicularcancer. Accessed date: December 1, 2022.
|
| [3] |
Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 2018; 97(37):e12390.
|
| [4] |
Idrees MT, Ulbright TM, Oliva E, et al. The World Health Organization 2016 classification of testicular non-germ cell tumours: A review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017; 70(4):513-521.
|
| [5] |
Gentile G, Rizzo M, Bianchi L, et al. Testis sparing surgery of small testicular masses: Retrospective analysis of a multicenter cohort. J Urol 2020; 203(4):760-766.
|
| [6] |
Boormans JL, Mayor de Castro J, Marconi L, et al. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: A systematic review by the testicular cancer guidelines panel. Eur Urol 2018; 73(3):394-405.
|
| [7] |
Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: Systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 2007; 51(1):175-183; discussion 183-185.
|
| [8] |
Demirci A, Başar H. Effects of epidemiological risk factors on prognosis in testicular cancer. Int Urol Nephrol 2023; 55(1):51-59.
|
| [9] |
Leão R, Ahmad AE, Hamilton RJ. Testicular cancer biomarkers: A role for precision medicine in testicular cancer. Clin Genitourin Cancer 2019; 17(1):e176-e183.
|
| [10] |
Omri N, Kamil M, Alexander K, et al. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume. Prostate 2020; 80(16):1444-1449.
|
| [11] |
Herr HW. The concept of lymph node density-Is it ready for clinical practice? J Urol 2007; 177(4):1273-1275; discussion1275-1276.
|
| [12] |
Hsieh ML, Huang ST, Huang HC, Chen Y, Hsu YC. The reliability of ultrasonographic measurements for testicular volume assessment: Comparison of three common formulas with true testicular volume. Asian J Androl 2009; 11(2):261-265.
|
| [13] |
Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol 2015; 68(6):1054-1068.
|
| [14] |
O'Sullivan B, Brierley J, Byrd D, et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol 2017; 18(7):849-851.
|
| [15] |
Gori S, Porrozzi S, Roila F, Gatta G, De Giorgi U, Marangolo M. Germ cell tumours of the testis. Crit Rev Oncol Hematol 2005; 53(2):141-164.
|
| [16] |
Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005; 5(3):210-222.
|
| [17] |
Song G, Xiong GY, Fan Y, et al. The role of tumor size, ultrasonographic findings, and serum tumor markers in predicting the likelihood of malignant testicular histology. Asian J Androl 2019; 21(2):196-200.
|
| [18] |
Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): Results from the IGCCCG update consortium. J Clin Oncol 2021; 39(14):1563-1574.
|
| [19] |
Choo R, Thomas G, Woo T, et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005; 61(3):736-740.
|
| [20] |
Ediz C, Ihvan A. What is the significance of rete testis invasion by malign germ cell tumor and does hilum predict metastasis? Urol Int 2019; 103(1):49-54.
|
| [21] |
Atsü N, Eskiçorapçi S, Uner A, et al. A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int 2003; 92(1):32-35.
|
| [22] |
Li X, Guo S, Wu Z, et al. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World J Urol 2015; 33(9):1351-1357.
|
| [23] |
Blok JM, Pluim I, Daugaard G, et al. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: A systematic review and meta-analysis. BJU Int 2020; 125(3):355-368.
|
PDF
(370KB)
